Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Today's Bonus Story HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?Written by Jordan Chussler. Published 11/19/2025. 
Key Points - Shares of HIMS have seen gains of 173% and 146% this year, but they’ve also seen massive double-digit corrections after each run-up in price.
- The company’s management was able to achieve profitability just three years after its IPO.
- Analysts’ forecast an average 12-month price target nearly 25% higher than where the stock is trading today.
Most of the health care sector's headlines are dominated by Big Pharma giants. Legacy companies, including AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK)—and their lineup of game-changing drugs—receive the lion's share of attention. But one newer company is starting to make a splash, and investors seeking growth opportunities in health care should be paying attention. Founded in November 2017, Hims & Hers Health (NYSE: HIMS) went public in January 2021. By the end of 2024, the consumer-focused health platform posted its first year of profitability, reporting net income of $126 million. Trump's Next Export Ban Could Reshape the Global Economy
It's not semiconductors, AI chips or quantum computers. But none of those technologies can exist without it. On January 19th, 2026, Trump is expected to ban exports of something every tech company desperately needs—forcing them all to relocate to U.S. soil. See what he's about to ban here… While that figure is small compared with mega-cap giants like Pfizer, it demonstrates a level of discipline rarely seen among companies fewer than five years after their IPOs. That, combined with operations at the intersection of several high-demand industries, makes Hims & Hers Health an intriguing buy-and-hold prospect. A Turbulent Year for Shareholders On the fundamentals side, the young company's debt management has been solid. That strength is underscored by a nearly 244% increase in net cash provided by operating activities from 2023 to 2024. When Hims & Hers Health reported Q3 financials on Nov. 3, it missed on EPS by just $0.03 and beat on revenue, with $598.98 million representing a 49.2% year-over-year increase. In his remarks, CEO and cofounder Andrew Dudum said, "At the end of the quarter, subscribers using personalized solutions grew 50% year-over-year, helping drive nearly 50% in year-over-year revenue growth." Most notably, the company's debt-to-equity ratio of 1.67 and its forward price-to-earnings (P/E) ratio of 52.79—an improvement from its trailing 12-month P/E of 67.33—suggest these metrics could support earnings growth of more than 79% next year, from $0.29 per share to about $0.52 per share. Since 2021, Hims & Hers Health has averaged annual earnings before interest, taxes, depreciation, and amortization (EBITDA) growth of 37.14%, revenue growth of 77.85%, and earnings per share (EPS) growth of 169.63%. Despite these robust fundamentals, 2025 has required a strong stomach for HIMS shareholders. The stock's performance this year has been a roller-coaster, with rapid advances followed by steep declines. From Jan. 2 to Feb. 19, HIMS gained nearly 173% before giving back more than 63% by April 22. By May 19 it had climbed nearly 146% again, then plunged 36% by June 25. It regained about 60% by the end of July, and at the time of writing the stock is down roughly 45% from that recent high. HIMS Is at the Center of Multiple High-Growth Industries Still, since going public the stock is up almost 139%. Hims & Hers Health has shown rapid growth while management has maintained disciplined financials. The company's accessible, direct-to-consumer telehealth model places it at the intersection of several high-growth markets. According to market consultancy Grand View Research, the sexual health supplement market is projected to grow at a compound annual growth rate (CAGR) of 10.4% from 2024 through 2030. The hair-thinning market is projected to expand at a CAGR of 10.85% over the same period, while the telehealth market is expected to grow at a CAGR of 24.68%. Perhaps most notably, Hims & Hers Health also offers compounded GLP-1 injections that contain the same active ingredient found in Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The GLP-1 weight-loss market is forecast to grow at a CAGR of about 18.54% during that period. Additionally, Dudum said on the company's Q3 earnings call that Hims & Hers Health is in ongoing discussions with Novo Nordisk to distribute both injectable and oral formulations of Wegovy on the Hims & Hers platform, pending FDA approval. Here's What Wall Street Thinks of HIMS Ten of 15 analysts covering Hims & Hers Health rate it a Hold, and the consensus rating is Reduce. Still, the 15-analyst average 12-month price target is $45.27, implying potential upside of about 24.5%. However, the current level of short interest may give prospective investors pause: it stands at a significant 37.54% of the company's float. For longer-term investors, though, institutional ownership—nearly 64%—offers a vote of confidence. Reinforcing the institutional bullishness, over the past 12 months 425 institutional buyers have injected $2.31 billion, while 194 institutional sellers have withdrawn $1.17 billion.
| 
Post a Comment
Post a Comment